Navigation Links
Burrill Merchant Banking Advises Pfizer Inc. on Dermatology Portfolio Divestment
Date:7/14/2009

SAN FRANCISCO, July 14 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to Pfizer Inc. on its recently-completed divestment of three investigational compounds for dermatological conditions to Graceway Pharmaceuticals, LLC. Financial terms of the agreement were not disclosed.

The most advanced product is a novel Cholesterol-Aceyltransferase (ACAT) inhibitor currently in Phase 2 development for the treatment of oily skin and acne. An earlier-stage Stearoyl CoA Desaturase 1 (SCD1) Inhibitor targeting the same indication was also included in the transaction, as was an Activin-Like Kinase 5 (ALK-5) inhibitor currently in preclinical development for reducing scarring resulting from surgery or trauma.

Simultaneous with the out-licensing transaction, Pfizer and Graceway executed a Master Services and Supply Agreement under which Pfizer agreed to provide clinical and other development support for the three licensed compounds.

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies in identifying, negotiating and closing strategic transactions. Service lines include:

  • Mergers & Acquisitions
  • Strategic Partnering
  • Spin-Outs and Divestitures
  • Financing (Private Placements)
  • Advisory Services to define the role of transactions in achieving strategic objectives

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report, which tracks the progress of the global biotechnology industry and annual "State of the Industry" report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd annual report on the industry. The 470-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond. For more information, visit http://www.burrillandco.com


'/>"/>
SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Burrill & Company Announces Promotions
2. Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
3. Biotech Finishes on a High in August, Burrill Report Says
4. Retail Union Head Blasts Merchants Group for Opposition to Health Care Reform
5. Network Merchants, Inc (NMI) Founders Donate $50,000 to Schaumburgs Childrens Home & Aid
6. New York Merchants Protective Co. Renews CSAA Five Diamond Certification
7. New Certification Seal Identifies Merchants Committed to Fighting Identity Theft
8. Simon Property Group Selects New York Merchants Protective Co., Inc. for Fire-alarm Services
9. United Physicians, P.C. Selects National City, Now Part of PNC, for Physician Banking Program
10. Cord Blood Registry Supports Family Cord Blood Banking Act
11. BancTec Provides Thought Leadership at 7th Annual Medical Banking Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: